Scarpa A, Ralli M, Cassandro C, et al. - Researchers tested the safety and effectiveness of low-dose intratympanic (IT) gentamicin on vertigo attacks in Meniere disease (MD) utilizing a clinical symptomatology-based method in which administration was repeated only when vertigo attacks recurred, with an interval of 2 weeks between injections. The study sample consisted of 48 patients with unilateral intractable MD. All patients got one to five injections of 0.5 ml of 10 mg of gentamicin (80 mg/2 ml) with an injection interval of 2 weeks. Investigators found that before treatment patients had an average of 4.4 vertigo attacks/month and after treatment the average number declined to 0.52. Findings suggested that low-dose IT gentamicin administration based on clinical symptomatology can produce a satisfactory control of vertigo attacks after treatment. They observed that such protocol had an impact mainly on the vestibular function as illustrated by the significant reduction in VOR gain in the affected side avoiding a cochlear destruction. There was no hearing deterioration in all patients treated.